BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
178.5 USD -0.67% Intraday chart for BeiGene, Ltd. +18.36% -1.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BeiGene Says FDA Accepts License Application For Tevimbra For Gastric Cancers MT
BeiGene’s Non-Small Cell Lung Cancer Drug Gets Recommended for Approval by European Regulator MT
BeiGene's Q4 2023 Net Loss Narrows as Revenue Increases; Misses Estimates MT
BeiGene's Q4 Net Loss Narrows, Revenue Rises MT
European Medicines Agency Panel Backs BeiGene's Non-small Cell Lung Cancer Treatment MT
BeiGene, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BeiGene Secures Recommendation for Tislelizumab's Approval in Europe as Non-Small Cell Lung Cancer Treatment MT
Earnings Flash (BGNE) BEIGENE Reports Q4 Revenue $634.4M MT
BeiGene, Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer CI
Nomura Adjusts Beigene’s Price Target to HK$150.60 From HK$162.05, Keeps at Buy MT
Tech, Consumer Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading MT
Beigene, Ltd. Receives Health Canada Authorization for the Use of BRUKINSA®? (zanubrutinib) in Combination with Obinutuzumab CI
Asian Equities Traded in the US as American Depositary Receipts Move Lower in Friday Trading; End Week Down 1% MT
BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib) CI
Beigene, Ltd. Announces Board Changes CI
BeiGene, Ltd. Announces Board Changes CI
Asian Equities Traded in the US as American Depositary Receipts Slump in Tuesday Trading MT
Transcript : BeiGene, Ltd. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01:30 PM
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Friday Trading MT
BeiGene Says Cancer Treatment Label Update Gets Approved by FDA MT
BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia CI
Certain Options of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2023. CI
Certain Restricted Share Units of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2023. CI
Certain A Shares of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2023. CI
Chart BeiGene, Ltd.
More charts
BeiGene, Ltd. is a global biotechnology company. The Company is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. It has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The Company has in licensed the rights to distribute 13 approved medicines for the China market. BRUKINSA is a second-generation small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
178.5 USD
Average target price
270.1 USD
Spread / Average Target
+51.32%
Consensus
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW